Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Blackwell Hopeful New Agents Will Advance HER2+ Breast Cancer Care

October 25th 2016

Kimberly L. Blackwell, MD, discusses the latest advances for patients with HER2-positive breast cancer and provides insight on the hurdles that still remain.

Ribociclib Results Hailed as Practice Changing in HR+ Breast Cancer

October 24th 2016

Gabriel N. Hortobagyi, MD, discusses the MONALEESA-2 trial, in which the addition of the CDK4/6 inhibitor ribociclib to letrozole significantly improved progression-free survival in women with hormone receptor–positive advanced breast cancer.

Dr. Marcom Reflects on Field of HR+ Breast Cancer

October 22nd 2016

Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses how the field of hormone receptor (HR)-positive breast cancer has evolved.

Dr. Anders on Challenge of Brain Mets in Breast Cancer

October 20th 2016

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses why brain metastases is such a prominent issue in patients with breast cancer in an interview during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.

Novel HER2-Targeting Antibody-Drug Conjugate Shows Broad Antitumor Activity

October 20th 2016

A novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.

Combinations With Abemaciclib Show Long-Term Disease Control in Advanced Breast Cancer

October 19th 2016

Abemaciclib plus tamoxifen, trastuzumab, or one of many endocrine-based therapies demonstrated significant antitumor activity and clinical benefit in patients with advanced breast cancer.

Dr. Blackwell on Treatment Landscape of HER2+ Breast Cancer

October 19th 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the available treatments for patients with HER2-positive breast cancer, as well as other agents that are in development.

Dr. McGuire on Evolving Role of Surgery in Metastatic Breast Cancer

October 19th 2016

Kandace McGuire, MD, associate professor of Surgery, UNC Department of Surgery, Division of Surgical Oncology, UNC School of Medicine, discusses the evolving role of surgery in the treatment of patients with metastatic breast cancer.

Dr. Sanft on Treatment Options in HER2-Positive Breast Cancer

October 18th 2016

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discusses standard treatment options for patients with HER2-positive breast cancer.

Dr. Hortobagyi on MONALEESA-2 Trial Results in HR+ Breast Cancer

October 18th 2016

Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Dr. Arnedos on Next Steps Following the POP Randomized Trial in Breast Cancer

October 15th 2016

Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, shares some of her thoughts regarding next steps following the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer

October 14th 2016

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses MYL-1401O, a proposed biosimilar for trastuzumab (Herceptin), in patients with HER2-positive metastatic breast cancer.

Entinostat Anchors New Combo in HR+ Breast Cancer Study

October 13th 2016

A dual approach to overcoming resistance to endocrine therapy in patients with advanced hormone receptor-positive breast cancer is under investigation in a phase III trial that adds the novel drug entinostat to standard exemestane therapy after disease progression.

Dr. Verma on Treatments in the Neoadjuvant Setting of HER2-Positive Breast Cancer

October 13th 2016

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses the overall treatment paradigm in the neoadjuvant setting of HER2-positive breast cancer.

Expert Discusses Importance of Tomosynthesis in Breast Cancer

October 12th 2016

While tomosynthesis has been described by the oncology community as one of the biggest improvements in breast cancer screening, the technology that renders 3D-like images of the breast does carry limitations.

Dr. Finn on the Phase III PALOMA-2 Trial in ER+ Breast Cancer

October 11th 2016

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

Role of PARP Inhibitors Evolving in Triple-Negative Breast Cancer

October 11th 2016

PARP inhibitors still have a place in the treatment paradigm of triple-negative breast cancer, but the role of these agents are significantly evolving.

Fulvestrant Bests Anastrozole in Phase III Breast Cancer Study

October 11th 2016

First-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with HR-positive advanced breast cancer.

Ribociclib Leads to Major PFS Increase in HR+ Metastatic Breast Cancer

October 8th 2016

Postmenopausal women with hormone receptor-positive metastatic breast cancer had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase 4/6 inhibitor ribociclib to endocrine therapy.

Dr. Llombart-Cussac on the CASCADE Study in Metastatic Breast Cancer

October 8th 2016

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the CASCADE study, which assessed declines in treatment efficacy over time in patients with metastatic breast cancer, during an interview at the 2016 ESMO Congress.